AlAmeri Mubarak, Epstein Miran, Johnston Atholl
Clinical Pharmacology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK.
Pharm World Sci. 2010 Dec;32(6):691-5. doi: 10.1007/s11096-010-9429-2.
Cost containment-driven drug substitution, whether generic or therapeutic, is defined as switching to another drug because it is cheaper. So far, such substitutions have drawn their public legitimacy from the general belief that they would not compromise the clinical interests of patients and certainly not violate their right to decline them if they did. This article does not enter the debate on whether or not such substitutions must give exclusive priority to the patient's interests and choices in order to be ethical. Indeed, it acknowledges the plurality of views on this matter. It simply argues that when such substitutions involve a cheaper drug that is known to have different effects and side effects, or even a drug whose effects and side effects are unknown, they are potentially deleterious to the patient, and that no competent and well-informed patient would ever consent to them. Such substitutions are thus unethical in their very own terms.
成本控制驱动的药物替代,无论是通用名药物替代还是治疗性替代,都被定义为因另一种药物更便宜而进行换药。到目前为止,这种替代在公众层面的合理性源于一种普遍观念,即人们认为这不会损害患者的临床利益,而且如果真的有损害,肯定也不会侵犯患者拒绝换药的权利。本文不参与关于这种替代是否必须将患者的利益和选择置于首位才符合伦理的争论。事实上,本文承认对此事存在多种观点。本文只是认为,当这种替代涉及一种已知有不同效果和副作用的更便宜药物,甚至是一种效果和副作用不明的药物时,它们对患者有潜在危害,而且没有任何一位有行为能力且信息充分的患者会同意这种替代。因此,就其本身而言,这种替代是不道德的。